Published in Biotech Business Week, August 9th, 2004
During the quarter, MethylGene successfully completed its initial public offering (IPO) and began trading its shares on the Toronto Stock Exchange under the symbol MYG.
Total revenues for the second quarter ended June 30, 2004, were $3.5 million compared to $755,000 for the same period last year. Total revenues for the first 6 months of 2004 were $5.0 million compared to $1.5 million for the first 6 months of the corresponding period last year.
For the second quarter of 2004, revenue consisted primarily of contract...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.